APA (7th ed.) Citation

Chen, H., Tu, H., Hu, Y., Fan, Y., Wu, G., Cang, S., . . . Wu, Y. (2025). A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001). Journal of hematology and oncology, 18(1), 3-10. https://doi.org/10.1186/s13045-024-01656-0

Chicago Style (17th ed.) Citation

Chen, Hua-Jun, et al. "A Phase II Trial of Anlotinib Plus EGFR-TKIs in Advanced Non-small Cell Lung Cancer with Gradual, Oligo, or Potential Progression After EGFR-TKIs Treatment (CTONG-1803/ALTER-L001)." Journal of Hematology and Oncology 18, no. 1 (2025): 3-10. https://doi.org/10.1186/s13045-024-01656-0.

MLA (9th ed.) Citation

Chen, Hua-Jun, et al. "A Phase II Trial of Anlotinib Plus EGFR-TKIs in Advanced Non-small Cell Lung Cancer with Gradual, Oligo, or Potential Progression After EGFR-TKIs Treatment (CTONG-1803/ALTER-L001)." Journal of Hematology and Oncology, vol. 18, no. 1, 2025, pp. 3-10, https://doi.org/10.1186/s13045-024-01656-0.